These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8679262)

  • 21. [Radioimmunodetection of cancer].
    Itoh K; Nishi S; Hata Y
    Nihon Rinsho; 1986 Mar; 44(3):729-42. PubMed ID: 3525900
    [No Abstract]   [Full Text] [Related]  

  • 22. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.
    Storto G; Buchegger F; Waibel R; Kuenzi G; Offord RE; Schubiger PA; Gillet M; Delaloye AB
    Cancer Biother Radiopharm; 2001 Oct; 16(5):371-9. PubMed ID: 11776754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic use of radiolabeled antibodies for cancer.
    Harrison KA; Tempero MA
    Oncology (Williston Park); 1995 Jul; 9(7):625-31 DISC 634, 636, 641. PubMed ID: 8924373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Basic study for immunoscintigraphy of ovarian cancer using 99mTc labeled F(ab')2 fragments of monoclonal antibody].
    Sugiyama S
    Kaku Igaku; 1994 Apr; 31(4):327-36. PubMed ID: 8196229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunoscintigraphy with 99mTc-labelled anti-CEA monoclonal antibody in colorectal carcinoma.
    Vieira MR; Rodrigues M; Salgado L; Santos R; de Almeida JC; Manoel LO; de Almeida JM
    Eur J Surg Oncol; 1993 Jun; 19(3):294-9. PubMed ID: 8314389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical assessment of 111In-CYT-103 immunoscintigraphy in ovarian cancer.
    Surwit EA; Childers JM; Krag DN; Katterhagen JG; Gallion HH; Waggoner S; Mann WJ
    Gynecol Oncol; 1993 Mar; 48(3):285-92. PubMed ID: 8462896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnosis and treatment of neoplasms with radionuclide-labeled antibodies.
    DeLand FH; Goldenberg DM
    Semin Nucl Med; 1985 Jan; 15(1):2-11. PubMed ID: 2580353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunoscintigraphy of tumours: possibilities and limitations.
    Pimm MV; Perkins AC; Baldwin RW
    Behring Inst Mitt; 1984 May; (74):61-71. PubMed ID: 6332618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Production and characterisation of a C595 antibody-99mTc conjugate for immunoscintigraphy of bladder cancer.
    Simms MS; Murray A; Denton G; Scholfield DP; Price MR; Perkins AC; Bishop MC
    Urol Res; 2001 Feb; 29(1):13-9. PubMed ID: 11310209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor markers for radiommunodetection of cancer.
    McIntire KR
    Cancer Res; 1980 Aug; 40(8 Pt 2):3083-5. PubMed ID: 7397704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiolabelled monoclonal antibodies in oncology. I. Technical aspects.
    Britton KE; Granowska M; Mather SJ
    Nucl Med Commun; 1991 Jan; 12(1):65-76. PubMed ID: 2023694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 99mTc-labeled divalent and tetravalent CC49 single-chain Fv's: novel imaging agents for rapid in vivo localization of human colon carcinoma.
    Goel A; Baranowska-Kortylewicz J; Hinrichs SH; Wisecarver J; Pavlinkova G; Augustine S; Colcher D; Booth BJ; Batra SK
    J Nucl Med; 2001 Oct; 42(10):1519-27. PubMed ID: 11585867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monoclonal antibody 138H11 in immunoscintigraphy of human kidney tumors--in vitro results.
    Rachel U; Baum RP; Fischer P; Jonas D; Scherberich JE
    Investig Urol (Berl); 1994; 5():66-8. PubMed ID: 7719323
    [No Abstract]   [Full Text] [Related]  

  • 34. Breast cancer 99mTc SM3 radioimmunoscintigraphy.
    Granowska M; Biassoni L; Carroll MJ; Howell R; Mather SJ; Ellison D; Granowski A; Britton KE
    Acta Oncol; 1996; 35(3):319-21. PubMed ID: 8679263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunoscintigraphy with a technetium-99m labelled anti-epithelial growth factor receptor antibody in patients with non-small cell lung cancer.
    Schillaci O; Danieli R; Picardi V; Bagni O; Di Loreto M; Scopinaro F
    Anticancer Res; 2001; 21(5):3571-4. PubMed ID: 11848525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone marrow immunoscintigraphy versus conventional bone scintigraphy in the diagnosis of skeletal metastases in urogenital malignancies.
    Zoeller G; Sandrock D; Munz DL; Ringert RH
    Eur Urol; 1994; 26(2):141-4. PubMed ID: 7957469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CEA-immunoscintigraphy with 99m-technetium correlates with tumour cell differentiation in colorectal cancer.
    Wittig BM; Hach A; Hahn K; Meyer zum Büschenfelde KH; Dippold WG
    Eur J Cancer; 1993; 29A(9):1327-9. PubMed ID: 8343279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunoscintigraphy with three step monoclonal pretargeting technique in diagnosis of uveal melanoma: preliminary results.
    Modorati G; Brancato R; Paganelli G; Magnani P; Pavoni R; Fazio F
    Br J Ophthalmol; 1994 Jan; 78(1):19-23. PubMed ID: 8110692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Numerical selection of optimal tumor imaging agents with application to engineered antibodies.
    Williams LE; Wu AM; Yazaki PJ; Liu A; Raubitschek AA; Shively JE; Wong JY
    Cancer Biother Radiopharm; 2001 Feb; 16(1):25-35. PubMed ID: 11279795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preliminary study on immunoscintigraphy of a murine lymphoma using technetium-99M labeled chicken antibody.
    Subbiah K; Myleru U; Ananthanarayanan M
    Tumori; 2000; 86(3):233-7. PubMed ID: 10939605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.